

## Clariant introduces new high- performing pharma excipients at CPHI India 2024

27 November 2024 | News

**Expanded range includes excipients for different applications such as for sensitive active pharmaceutical ingredients**



Clariant has introduced the company's latest portfolio of products for the healthcare industry at the upcoming CPHI India tradeshow in Delhi NCR, being held on November 26 through 28, 2024. This year's event will showcase Clariant Health Care's Made in India products, local Bonthapally operations, and expertise in biologics, generics, and excipient production. This includes a range of reliable, high-quality, cost-effective, and tailored solutions for the growing Indian healthcare market.

Excipients are essential to the stability, bioavailability, and efficacy of active pharmaceutical ingredients (APIs) and the global excipients market is expected to grow at a compound annual growth rate (CAGR) of 6 to 7%. This increase has been driven by rising demand for specialty drugs and biologics, stricter regulatory standards, and the increasing needs of aging populations worldwide.

To ensure the uninterrupted supply of ultra-pure excipients, Clariant has combined the global expertise of Clariant International Ltd (Switzerland) with local manufacturing capabilities in India to offer customized solutions for the evolving needs of the pharmaceutical industry. India is now a global leader in pharmaceutical manufacturing, supplying over 50% of global vaccines and 40% of generic drugs.

Parenteral excipients manufactured in Bonthapally facility are equipped with advanced clean room environments, adhering to the highest international standards of sterility and purity to ensure the efficacy and safety of the excipients. Through the local production of key excipients like VitiPure Superior and Meglumine, Clariant's Bonthapally facility plays a central role in supporting the global healthcare supply chain.

Clariant introduces VitiPure LEX 3350 S, VitiPure LEX 4000 S, and Polyglykol 1450 S to solve API delivery and bioavailability challenges.

Compared to the standard excipient grade, all three superior products improve the stability of the finished API formulations. In addition, the steel packaging with nitrogen purging assures low levels of peroxide formation during product storage.